An experimental Novartis AG treatment for a form of advanced breast cancer slashed the risks of death and the disease progressing in a study, paving the way for the Swiss drugmaker to seek regulatory approval in the U.S. and Europe by the end of the year.
Novartis expects to win the first approval for the drug, ribociclib, by the end of June next year, Alessandro Riva, global head of oncology development and medical affairs at the Basel, Switzerland-based company, said in an interview.
Ribociclib, in combination with the older breast-cancer medicine letrozole, cut the risk of worsening or death by 44 percent over letrozole alone in a study of more than 600 people, Novartis said on Saturday. M
Novartis expects to win the first approval for the drug, ribociclib, by the end of June next year, Alessandro Riva, global head of oncology development and medical affairs at the Basel, Switzerland-based company, said in an interview.
Ribociclib, in combination with the older breast-cancer medicine letrozole, cut the risk of worsening or death by 44 percent over letrozole alone in a study of more than 600 people, Novartis said on Saturday. M
